Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation method for new polypeptide having tissue protection activity, and application of new polypeptide in treatment

An active and alkaline technology for tissue protection, applied in the field of medicine and biology, can solve problems such as increased intracranial pressure, compression of the life center, and impact on heart function

Inactive Publication Date: 2013-04-03
高再兴
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, inflammation is also potentially very harmful to the body. Severe allergic reactions can endanger the life of the patient; the organization of fibrinous exudate in the pericardial cavity can form constrictive pericarditis, which in turn affects heart function; occurs in the brain parenchyma or Inflammation of the meninges can cause increased intracranial pressure, and even form a brain herniation, resulting in compression of the life center and death of the patient; in addition, acute inflammation and edema of the vocal cords can lead to suffocation, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method for new polypeptide having tissue protection activity, and application of new polypeptide in treatment
  • Preparation method for new polypeptide having tissue protection activity, and application of new polypeptide in treatment
  • Preparation method for new polypeptide having tissue protection activity, and application of new polypeptide in treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Example 1: Chemical synthesis and purification of polypeptides:

[0019] Taking the amino acid sequence shown in SEQ ID No.2 as an example, the polypeptide is chemically synthesized.

[0020] Synthesized by Fmoc solid-phase method:

[0021] Adopt solid-phase synthesis instrument, select the val-2 chlorotrityl resin of 0.5 gram as initial resin, add successively in the synthesis reaction tube:

[0022] Fmoc-leu, Fmoc-gly, Fmoc-ala, Fmoc-Asp(otbu)fmoc-asp(otbu), Fmoc-ala, Fmoc-pro, Fmoc-lys(boc), FMoc-gly, FMoc-pro, Fmoc- pro, FMoc-pro, Fmoc-Glu(otbu), Fmoc-gly.

[0023] Add DIC / DMF solution, HOBT / DMF solution and DMF solution to the reagent bottle. Start the synthesis instrument and connect it to the computer, enter the synthesis program, and start the synthesis.

[0024] Compositing post-processing:

[0025] Take the resin out from the synthesis reaction column, put it into a glass container with a sintered glass filter at the bottom, and use DMF (dimethylformamide...

Embodiment 2

[0041] Embodiment 2: stability test

[0042] The polypeptide of the present invention was incubated at 40°C for 76 days and 120 days to test its stability. The stability test was determined by HPLC method. The concentration of polypeptide in aqueous solution is 0.2% (w / v): column, Kromasil100, 5u, 250x 4.6mm; mobile phase, water / acetonitrile solution of 0.1% trifluoroacetic acid (0 to 50vol.%), within 25 minutes Gradient elution, flow rate 1ml / min; detection: UV, 218nm.

[0043] For comparison, the free polypeptide and its monoacetate salt were used.

[0044] Table 1

[0045]

[0046] It can be shown from the data in Table 1 that the stability of the polypeptide of the present invention is very high. The solution still has more than 97% of the target substance after 120 days at 40°C.

Embodiment 3

[0047] Embodiment 3: the toxicity of polypeptide of the present invention

[0048] The acute toxicity of the polypeptide of the present invention is determined by intragastric administration and injection in mice.

[0049] Solution preparation:

[0050] Use 25 mg of the polypeptide of the present invention, add sterilized water to 20 ml, and prepare a solution with a concentration of 1.25 mg / ml for oral gavage.

[0051] Use 25 mg of the polypeptide of the present invention, add sterilized water to 10 ml, and prepare a solution with a concentration of 2.5 mg / ml for intraperitoneal injection.

[0052] Dosage Calculation:

[0053] The volume of oral gavage administration to mice is 40 ml / kg body weight, so the administration dose is: 1.25 mg / ml*40 ml / kg=50 mg / kg.

[0054] The volume of intraperitoneal injection in mice is 20ml / kg body weight, so the dosage is: 2.5mg / ml*20ml / kg=50mg / kg.

[0055] Take 80 healthy mice and divide them into four groups for experiment. After adminis...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a new polypeptide having a tissue protective activity. The present invention discloses a sequence, a structure and a preparation method of the polypeptide. The polypeptide has a good tissue and organ protection effect, especially provides good cure effects for inflammations of a plurality of tissues, and has characteristics of no toxicity, safety, and wide medicinal and medical application prospects.

Description

technical field [0001] The invention belongs to the field of medical biotechnology. As a tissue protective polypeptide, the polypeptide of the invention can protect almost all organs and tissues of the body, especially for various tissue inflammations, and has good protection, treatment and healing effects. The invention relates to technologies such as solid-phase chemical synthesis of polypeptides, large-scale purification and freeze-drying of polypeptides, measurement of physical and chemical properties, and therapeutic applications. Background technique [0002] Exogenous and endogenous injury factors can cause a variety of damaging lesions in cells. At the same time, a series of complex reactions occur locally and throughout the body to confine and eliminate injury factors, remove and absorb necrotic tissue, cells, and repair damage, this is the body's defensive response called inflammation. Inflammation is a very common and important basic pathological process. Trauma ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/06C07K7/08A61K38/08A61K38/10A61P31/00A61P29/00
Inventor 不公告发明人
Owner 高再兴
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com